Europa Press6d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA
The trial investigates the efficacy, safety and tolerability of QUTENZA ® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S ...
pressat6d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...
ots6d
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neur
The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after ...